

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop PCT/Missing Requirements, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

June 8, 2006

David Saliwanchik

David R. Saliwanchik, Patent Attorney

Patent Application
Docket No. GJE-7631
Serial No. 10/535,609

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ian C. Bathurst *et al.*
Serial No. : 10/535,609
Filed : May 19, 2005
Conf. No. : 7257
For : Composition and Method for Treating Inflammatory Diseases
Using Protease Inhibitors

Mail Stop PCT/Missing Requirements
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO FILE APPLICATION WITHOUT
SIGNATURE OF JOINT INVENTOR

Sir:

Pursuant to 37 CFR 1.47(a), the applicants hereby petition to file the above-identified application without the signatures of joint inventors Ian C. Bathurst, Philip A. Pemberton, David J. Sundin and Philip J. Barr. The applicants have been unsuccessful in obtaining the signatures of these co-inventors.

Attached herewith are various documents confirming that efforts have been made to obtain the signatures of the non-signing inventors.

Docket No. GJE-7631
Serial No. 10/535,609

Please charge the petition fee of \$130 to Deposit Account 19-0065. The Commissioner is hereby authorized to charge any additional fees as required by 37 CFR 1.17(h) to Deposit Account No. 19-0065. Two copies of this Petition are enclosed for authorization of charges to the Deposit Account.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address : P.O. Box 142950
Gainesville, FL 32614-2950

DRS/la


Enclosures: as stated above

06/16/2006 ATRAN1 00000133 190065 10535609
03 FC:1464 130.00 DA

Brais Annie

From: Phil Barr [PBarr@arrivapharm.com]
Sent: Monday, March 27, 2006 5:18 PM
To: Brais Annie
Cc: Greg Ikonen
Subject: RE: US Patent application USSN 10/535,609 - Our Ref.: PA-0019-AP/US

Dear Annie,
Thank you for your e-mail, which I forwarded to our Patent Counsel, Leslie Mooi of Heller Ehrman. I believe that she has already spoken to you by phone.
I will look into obtaining signatures on the inventors' declarations, but as many of the inventors are no longer at Arriva, it will take some time, assuming I can track them down. I would suggest you seek an extension of the deadline for filing these.



Best regards,
Phil Barr
Greg Ikonen
Arriva Pharmaceuticals

The information contained in this email message may be privileged, confidential and protected from disclosure. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think that you have received this email message in error, please notify the sender by reply email and delete the message and any attachments.

-----Original Message-----

From: Brais Annie [mailto:a.brais@prometic.com]
Sent: Friday, March 10, 2006 6:47 AM
To: Phil Barr
Cc: Matthew Dean
Subject: US Patent application USSN 10/535,609 - Our Ref.: PA-0019-AP/US
Importance: High

Dear Mr. Barr,

I am seeking your assistance to obtain signatures from inventors in the above-reference US patent application.

We must file the *Declaration and Power of Attorney* together with an *Assignment* (from inventors to Arriva-ProMetic Inc.) with the USPTO as soon as possible.
Therefore, would you please print a copy of the attached documents and have them **signed and dated** by all the inventors listed thereon.
Please note that the **assignment must be witnessed**.

I would appreciate if you could send me a pdf copy or facsimile of the executed documents and have the originals follow by courier.
Please return the documents to my attention, before **March 25, 2006**, to enable me to respect the formalities deadline.

Do not hesitate to contact me if you have any questions.

3/28/2006

Brais Annie

From: Phil Barr [PBarr@arrivapharm.com]
Sent: Monday, March 27, 2006 5:18 PM
To: Brais Annie
Cc: Greg Ikonen
Subject: RE: US Patent application USSN 10/535,609 - Our Ref.: PA-0019-AP/US

Dear Annie,
Thank you for your e-mail, which I forwarded to our Patent Counsel, Leslie Mooi of Heller Ehman. I believe that she has already spoken to you by phone.
I will look into obtaining signatures on the inventors' declarations, but as many of the inventors are no longer at Arriva, it will take some time, assuming I can track them down. I would suggest you seek an extension of the deadline for filing these.

Best regards,
Phil Barr
Greg Ikonen
Arriva Pharmaceuticals

The information contained in this email message may be privileged, confidential and protected from disclosure. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think that you have received this email message in error, please notify the sender by reply email and delete the message and any attachments.

-----Original Message-----

From: Brais Annie [mailto:a.brais@prometic.com]
Sent: Friday, March 10, 2006 6:47 AM
To: Phil Barr
Cc: Matthew Dean
Subject: US Patent application USSN 10/535,609 - Our Ref.: PA-0019-AP/US
Importance: High

Dear Mr. Barr,


I am seeking your assistance to obtain signatures from inventors in the above-reference US patent application.

We must file the *Declaration and Power of Attorney* together with an *Assignment* (from inventors to Arriva-ProMetic Inc.) with the USPTO as soon as possible.
Therefore, would you please print a copy of the attached documents and have them signed and dated by all the inventors listed thereon.
Please note that the **assignment must be witnessed**.

I would appreciate if you could send me a pdf copy or facsimile of the executed documents and have the originals follow by courier.
Please return the documents to my attention, before **March 25, 2006**, to enable me to respect the formalities deadline.

Do not hesitate to contact me if you have any questions.

3/28/2006



MEMORANDUM TO FILE

From: Annie Brais
Date: March 22, 2006
Our file: PA-0019-AP
Project: rAAT Derm Formulation

Telephone conversation of this day with Ms. Lesley Moii, Attorney representing Arriva Pharmaceuticals, Inc. (tel. no. 650-324-6786), who inquired about the final deadline to file the declarations with the USPTO. I inform her that we are already into extension deadlines and that we are targeting **April 9th 2006** as the deadline to avoid unnecessary extra costs.

Ms. Moii mentioned that Arriva Pharmaceuticals wants to review the assignment and that she may not send it together with the declarations. I explain to her and emphasized on the fact that it would be easier for everyone if she could obtain the inventor's signatures all at once, even though there is no urgency to file it right away.

She confirms her intention to help me meet the April 9th, 2006 deadline for the declarations only.

I will follow-up with Ms. Moii during the week of **April 3rd, 2006**.

Brais Annie

From: Brais Annie
Sent: Friday, March 10, 2006 9:47 AM
To: 'PBarr@arrivapharm.com'
Cc: 'Matthew Dean'
Subject: US Patent application USSN 10/535,609 - Our Ref.: PA-0019-AP/US
Importance: High
Attachments: 07631us assignment.pdf; 07631us power.pdf

Dear Mr. Barr,

I am seeking your assistance to obtain signatures from inventors in the above-reference US patent application.

We must file the *Declaration and Power of Attorney* together with an *Assignment* (from inventors to Arriva-ProMetic Inc.) with the USPTO as soon as possible.

Therefore, would you please print a copy of the attached documents and have them signed and dated by all the inventors listed thereon.

Please note that the **assignment must be witnessed**.

I would appreciate if you could send me a pdf copy or facsimile of the executed documents and have the originals follow by courier.

Please return the documents to my attention, before **March 25, 2006**, to enable me to respect the formalities deadline.

Do not hesitate to contact me if you have any questions.

I thank you for your cooperation in this matter and look forward to receiving both documents signed.

Best regards,

Annie Brais

Patent and Trademark Coordinator/
Coordinatrice aux brevets et marques de commerce
ProMetic Life Sciences Inc./ProMetic Sciences de la Vie Inc.
8168 Montview Road
Mont-Royal (QC) H4P 2L7
Canada
Tel: (+1) 514-341-2115 #2249
Fax: (+1) 514-341-6227
mailto: a.brais@prometic.com

3/10/2006

Brais Annie

From: Matthew Dean [MDean@arrivapharm.com]
Sent: Tuesday, March 07, 2006 1:42 PM
To: Brais Annie
Cc: Phil Barr
Subject: RE: Question - Helen Gibson - Patent Application USSN 10/535,609

Annie,

We have contacted Helen and she was not sure what it is that you are looking for and I have discussed the matter with Phil Barr our CSO. Please forward any future question to his attention and copy me.

Matthew A. Dean, CPA

Vice President, Finance and Administration

Arriva Pharmaceuticals, Inc.

1010 Atlantic Ave.

Alameda, CA 94501

(510) 337-7883

mdean@arrivapharm.com

From: Brais Annie [mailto:a.brais@prometic.com]
Sent: Monday, March 06, 2006 12:27 PM
To: Matthew Dean
Subject: Question - Helen Gibson - Patent Application USSN 10/535,609
Importance: High

Dear Mr. Dean,

We were recently informed of Helen Gibson's departure from Arriva. We have been in contact with her to obtain some inventor's signatures related to formalities for US patent applications. In order to complete the work which was undertaken by Ms. Gibson, would you please advise who should be contacted to continue the work and obtain the missing signatures from inventors in this specific file?

I look forward to your reply and thank you for your time in answering my question.

Sincerely,

Annie Brais
Patent and Trademark Coordinator/

3/7/2006

Harnois Danielle

Harnois Danielle

From: Harnois Danielle
Sent: 22 juin 2005 10:54
To: Harnois Danielle
Subject: RE: rAAT Derm Formulation - national phase application in Canada and USA

Importance: High
Sensitivity: Confidential

Matthew,

I nevertheless need you to send back the Declaration and Power of Attorney form, duly executed by Ian, Phil B., Phil P. and Dave. If you send it today, I will receive it tomorrow June 22nd. Please also send a copy by fax.

Danielle Harnois
Senior Legal Counsel - IP
ProMetic Life Sciences Inc.
6100, Royalmount Avenue
Montreal (QC) H4P 2R2
ph: (514) 341-2115, #2227
fax: (514) 341-6227
<http://www.prometic.com>

-----Original Message-----

From: Harnois Danielle
Sent: 21 juin, 2005 15:00
To: 'Matthew Dean'
Subject: RE: rAAT Derm Formulation - national phase application in Canada and USA

Thank you Matthew. We would have expected an answer earlier.

Danielle

-----Original Message-----

From: Matthew Dean [<mailto:MDean@arrivapharm.com>]
Sent: 21 juin, 2005 15:00
To: Harnois Danielle
Subject: RE: rAAT Derm Formulation - national phase application in Canada and USA

Danielle,

Martin and Phil Barr had many discussions around the assignment of the patent with Michelle and how as an Arriva employee, the employee is contractually obligated to assign the patent to Arriva. Additionally, we are in current discussions with Pierre and Michelle regarding the JV so at this time no assignment to the JV will be consummated by Arriva.

Matthew A. Dean, CPA
Vice President, Finance and Administration
Arriva Pharmaceuticals, Inc.
2020 Challenger Dr., Suite 101
Alameda, CA 94501
(510) 337-7883
2006-06-05 11:08

Harnois Danielle
mdean@arrivapharm.com

-----Original Message-----

From: Harnois Danielle (mailto:d.harnois@prometic.com)
Sent: Monday, June 20, 2005 2:00 PM
To: Matthew Dean
Subject: rAAT Derm Formulation - national phase application in Canada and USA
Importance: High

Dear Matthew,

On May 31 2005, and again on June 13, we have sent you assignment forms and power of attorneys in relation to the abovementioned applications. It is now becoming urgent to file these documents. Could you please return these forms to me no later than June 22nd (next Thursday)?

If you have questions or if there is someone else in your organization I should contact for this matter, please let me know as soon as possible.

Best regards,

Danielle

Danielle Harnois
Senior Legal Counsel - IP
ProMetic Life Sciences Inc.
6100, Royalmount Avenue
Montreal (QC) H4P 2R2
ph: (514) 341-2115, #2227
fax: (514) 341-6227
<http://www.prometic.com>

Ce courrier électronique contient des informations provenant du Groupe ProMetic (Canada, Royaume-Uni, États-Unis) et peut être confidentiel ou contenir de l'information privilégiée. L'information qu'il contient est destinée exclusivement au destinataire ci-dessus mentionné. Si vous n'êtes pas le destinataire visé, toute divulgation, reproduction, utilisation ou distribution du contenu de ce courrier électronique est strictement interdite. Si vous avez reçu ce message par erreur, nous vous prions de nous en informer immédiatement par téléphone (514-341-2115) ou par courrier électronique en répondant à ce message. Veuillez par la suite détruire ce courrier électronique de votre ordinateur. Merci.

This electronic message transmission contains information from the ProMetic Group (Canada, UK, USA) and may be confidential or privileged. The information is intended to be for the use of the individual or entity named above. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is prohibited. If you have received this electronic transmission in error, please notify us by telephone (514-341-2115) or by electronic mail (reply) immediately and delete this e-mail message from your computer. Thank you.

Tracking:

Recipient

Harnois Danielle

Delivery

Delivered: 2005-06-22 10:54

Harnois Danielle

Harnois Danielle

From: Administrator
Sent: 22 juin 2005 11:01
To: Harnois Danielle
Subject: Delivery Status Notification (Relay)

Attachments: ATT404862.txt; FW: rAAT Derm Formulation - national phase application in Canada and USA



ATT404862.txt
(422 B)



FW: rAAT Derm
Formulation - na...

This is an automatically generated Delivery Status Notification.

Your message has been successfully relayed to the following recipients, but the requested delivery status notifications may not be generated by the destination.

mdean@arrivapharm.com

Relevé de transmission

Date/Heure
ID locale 1
ID locale 2

2005-06-13
514 341 6227

16:35:09

Transmission en-tête

Nom local 1

Prometic Life Sciences

Nom local 2

Ce document : confirmé
(image réduite et informations ci-dessous)
Taille du document : A4



PROMETIC

8168, chemin Montclair
Mont-Royal (Québec) H4P 2L7
Tél.: (514) 341-2115
Fax: (514) 341-6227
www.prometic.com

URGENT

Facsimile transmission

To: Mr. MATTHEW DEAN
Vice-President of Finance
Arrive Pharmaceuticals Inc.

Fax: 514-337-1251

CC:

FROM: Danielle Harnois

DATE: May 31, 2005

PAGE(s): 2 INCLUDING COVER PAGE

Re: National entry Phase - RAAT Denta Formulation patent
PCT/GB03/05049
Our ref: PA-0019-AP

Message:

Please find attached a copy of above-mentioned letter for your information. The original documents will follow by courier.

Thank you and best regards,

Danielle Harnois
Senior Legal Counsel, IP
Prometic Life Science Inc.

NOTE: If you did not receive all these pages or have any problems receiving, please call the following number: (514) 341-2115.

CONFIDENTIALITY / CONFIDENTIALITÉ: The contents of this fax is privileged and confidential and intended solely for the designated recipient(s). Any dissemination, distribution or copying of this fax, other than by the intended recipient, is strictly prohibited. If you have received this fax by error, please notify us immediately and we will arrange for its return to our office. / Le contenu de cet envoi, privilégié et confidentiel, ne concerne qu'un ou plusieurs destinataire(s) indiqué(s) ci-dessus. Il est interdit, par tout autre personnel, de le divulguer, le communiquer ou le reproduire. Si vous avez reçu cet envoi par erreur, veuillez nous en aviser immédiatement et nous ferons la nécessaire pour le récupérer.

Total pages numérisées : 9

Total pages confirmées : 9

| N° | Travail | Terminal distant | Heure de début | Durée | Pages | Ligne | Mode | Type travail | Résultats |
|-----|---------|------------------|---------------------|----------|-------|-------|------|--------------|-----------|
| 001 | 677 | 510 337 1251 | 16:32:44 2005-06-13 | 00:01:43 | 9/9 | 1 | PR | EH | TM24000 |

Abréviations :

EH: Envoi hôte

RH: Réception hôte

EA: Envoi en attente

IL: Interrogation locale

ID: Interrogation distante

EB: Enreg. bte aux lettres

IB: Impression bte aux lettres

TM: Terminé

EC: Échec

AU: Arrêt par l'utilisateur

AS: Arrêt par le système

RL: Relevé

G3: Groupe 3

PR: Problème résolu

Relevé de transmission

Date/heure
ID locale 1
ID locale 2

2005-06-01
514 341 6227

14:15:33

Transmission en-tête
Nom local 1
Nom local 2

Prometic Life Sciences

Ce document : confirmé
(image réduite et informations ci-dessous)
Taille du document : A4



5168, chemin Montclair
Mont-Royal (Québec) H4P 2L7
Tél.: (514) 341-2115
Fax: (514) 341-6227
www.prometic.com

Facsimile transmission

TO: Mr. MATTHEW DEAR
Vice-President of Finance
Arriva Pharmaceuticals Inc.

FAX 510-337-1251

C.C.

FROM: Danielle Harnois

DATE: May 31, 2005

PAGE(S): 2 INCLUDING COVER PAGE

Re: National entry Phase - rAAT Derm Formulation patent
PCT/GB00/05849
Our ref: PA-0019-AP

Message:

Please find attached a copy of above-mentioned letter for your information. The original documents will follow by courier.

Thank you and best regards,

Danielle Harnois
Senior Legal Counsel, IP
Prometic Life Science Inc.

NOTE: If you did not receive all these pages or have any problems receiving, please call the following number: (514) 341-2115.

CONFIDENTIALITY / CONFIDENTIALITÉ: The contents of this fax is privileged and confidential and intended solely for the designated recipient(s). Any dissemination, distribution or copying of this fax, other than by its intended recipient, is strictly prohibited. If you have received this fax by error, please notify us immediately and we will arrange for its return to our office. / Le contenu de cet envoi, privilégié et confidentiel, ne s'adresse qu'au(x) destinataire(s) indiqué(s) ci-dessus. Il est interdit, par toute autre personne, de le divulguer, le communiquer ou le reproduire. Si vous avez reçu cet envoi par erreur, veuillez nous en aviser immédiatement et nous ferons le nécessaire pour le récupérer.

Total pages numérisées : 2

Total pages confirmées : 2

| N° | Travail | Terminal distant | Heure de début | Durée | Pages | Ligne | Mode | Type travail | Résultats |
|-----|---------|------------------|---------------------|----------|-------|-------|------|--------------|-----------|
| 001 | 441 | 510 337 1251 | 14:14:26 2005-06-01 | 00:00:31 | 2/2 | 1 | PR | EH | TM19200 |

Abréviations :

EH: Envoi hôte

RH: Réception hôte

EA: Envoi en attente

IL: Interrogation locale

ID: Interrogation distante

EB: Enreg. bte aux lettres

IB: Impression bte aux lettres AU: Arrêt par l'utilisateur

TM: Terminé

EC: Échec

AS: Arrêt par le système

RL: Relevé

G3: Groupe 3

PR: Problème résolu



PROMETIC

8168, chemin Montview
Mont-Royal (Québec) H4P 2L7
Tél.: (514) 341-2115
Fax: (514) 341-6227
www.prometic.com

URGENT!

Facsimile transmission

TO : **MR. MATTHEW DEAN**
Vice-President of Finance
Arriva Pharmaceuticals Inc.

FAX: 510-337-1251

REMINDER

C.C.

FROM : **Danielle Harnois**

DATE: **May 31, 2005**

PAGE(S): **2 INCLUDING COVER PAGE**

Re: **National entry Phase – rAAT Derm Formulation patent**
PCT/GBO3/05049
Our ref: PA-0019-AP

Message :

Please find attached a copy of above-mentioned letter for your information. The original documents will follow by courier.

Thank you and best regards,

Danielle Harnois
Senior Legal Counsel, IP
ProMetic Life Science Inc.

NOTE: If you did not receive all these pages or have any problems receiving, please call the following number: (514) 341-2115.

CONFIDENTIALITY / CONFIDENTIALITÉ: The content of this fax is privileged and confidential and intended solely for its designated recipient(s). Any dissemination, distribution or copying of this fax, other than by its intended recipient, is strictly prohibited. If you have received this fax by error, please notify us immediately and we will arrange for its return to our office. / Le contenu de cet envoi, privilégié et confidentiel, ne s'adresse qu'au(x) destinataire(s) indiqué(s) ci-dessus. Il est interdit, par toute autre personne, de le divulguer, le communiquer ou le reproduire. Si vous avez reçu cet envoi par erreur, veuillez nous en aviser immédiatement et nous ferons le nécessaire pour le récupérer.

PROMETIC

BY FEDEX
With copy by fax (w/o enclosure)

May 31, 2005

Mr. Matthew Dean
Vice-President of Finance
Arriva Pharmaceuticals Inc.
2020 Challenger Drive
Alameda, CA 94501, USA

Subject : National entry phase –rAAT Derm Formulation patent
PCT/GB03/05049
Our ref : PA-0019-AP

Dear Matthew,

Please find attached the following documents to be signed by Phil Barr, Phil Pemberton, David Sundin and Ian Bathurst to complete the national entry phase of the above-mentioned patent application:

- Declaration and Power of Attorney (USA)
- Assignment (USA) (to be signed by each inventor before 2 witnesses)
- Assignment (Canada) (before 1 witness)

I also provide extra sets of copies for each inventor in case any one of them cannot attend a common signing session.

I would appreciate if you could return these documents to me at the address indicated below at your earliest convenience, with an advance copy by fax.

Do not hesitate to contact me if you have any question. Thank you for your collaboration in this matter.

Best regards,


Danielle Harnois
Senior Legal Counsel – IP
ProMetic Life Sciences Inc.

Encl.
c.c. Robert Perry, Gill Jennings & Every (UK)

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on an invention entitled
**COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING
 PROTEASE INHIBITORS**

the specification of which ☐ is attached hereto or

☐ was filed on 20 NOV 2003 as United States Application Number or PCT International Application Number PCT/GB03/05049 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for a patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

| Prior Foreign Application Number(s) | Country | Foreign Filing Date | Priority Not Claimed | Certified Copy Attached? | |
|--|---------|---------------------|--------------------------|-----------------------------|--------------------------|
| | | | | YES | NO |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

I hereby claim the benefit under 35 U.S.C 119(e) of any United States provisional applications(s) listed below.

Appln. No. 60/427702 Filing Date 20 NOV 2002

Appln. No. Filing Date

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Appln. No. Filing Date Parent Patent No.

Appln. No. Filing Date Parent Patent No.

Full name of
Third Inventor

David J. SUNDIN

Inventor's signature

Residence address

CA 94501, USA

Post Office address

c/o Arriva Pharmaceuticals Inc, 2020 Challenger Drive,
Alameda, CA 94501, USA

Country of Citizenship USA

Date of signature

Full name of
Fourth Inventor

James W MAYHEW

Inventor's signature

Residence address

CA 94954-1169, USA

Post Office address

c/o Dow Pharmaceuticals Sciences, 1330A Redwood Way,
Petaluma, CA 94954-1169, USA

Country of Citizenship USA

Date of signature

Full name of
Fifth Inventor

Arturo J. ANGEL

Inventor's signature

Residence address

CA 94954-1169, USA

Post Office address

Dow Pharmaceuticals Sciences, 1330A Redwood Way,
Petaluma, CA 94954-1169, USA

Country of Citizenship USA

Date of signature

Full name of
Sixth Inventor

Philip J. BARR

Inventor's signature

x

Residence address

CA 94501, USA

Post Office address

c/o Arriva Pharmaceuticals Inc, 2020 Challenger Drive,
Alameda, CA 94501, USA

Country of Citizenship United Kingdom

Date of signature

x


From: Origin ID: YULA (514) 341-2115
 Marie Papinuti
 ProMetric Life Sciences Inc.
 8168, chemin Montview



Mont-Royal, PQ H4P2L7
 CANADA

SHIP TO: (510) 337-1250 BILL SENDER
Mathew Dean
Arriva Pharmaceuticals Inc.
2020 Challenger Drive

Alameda, CA 94501
 US



These commodities, technology, or software were exported from Canada in accordance with the export administration regulations. Diversion contrary to Canadian law prohibited.

The Warsaw Convention may apply and will govern and in most cases limit the liability of Federal Express for loss or delay of or damage to your shipment. Subject to the conditions of the contract.

CONSIGNEE COPY - PLEASE PLACE IN POUCH

Ship Date: 31MAY05
 Actual Wgt: 1 LB
 System#: 4659587/INCA2000
 Account#: S *****

Total Weight: 1 LB

REF: Nicole Martin
 DESC-1: Documents Only
 DESC-2:
 DESC-3:
 DESC-4:

COUNTRY MFG:
 CARRIAGE VALUE: 0.00 CAD
 CUSTOMS VALUE: 0.00 CAD
 T/C: S 260182463 O/T: S 260182463
 SIGN: Marie Papinuti
 EIN/VAT:

IP ENVELOPE


TRK# 7922 9479 4046 FORM 0430

OAK A1

94501

-CA-US

XH OAKA



Shipping Label: Your shipment is complete This shipping label constitutes the air waybill for this shipment.

1. Use the "Print" feature from your browser to send this page to your laser or inkjet printer. Fold the printed page along the horizontal line.

2. Place 2 originals of the shipping label in the pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional charges, along with the cancellation of your FedEx account number.

employees, agents, and independent contractors. The terms "you" and "your" refer to the shipper, its employees, principals and agents. If your shipment originates outside the United States, your contract of carriage is with the FedEx subsidiary, branch or independent contractor who originally accepts the shipment from you. The term "package" means any container or envelope that is accepted by us for delivery, including any such items tendered by you utilizing our automated systems, meters, manifests or waybills. The term "shipment" means all packages which are tendered to and accepted by us on a single Air Waybill. AIR CARRIAGE NOTICE. For any international shipments by air, the Warsaw Convention, as amended, may be applicable. The Warsaw Convention, as amended, will then govern and in most cases limit FedEx's liability for loss, delay of, or damage to your shipment. The Warsaw Convention, as amended, limits FedEx's liability. For example in the U.S. liability is limited to \$9.07 per pound (20\$ per kilogram), unless a higher value for carriage is declared as described below and you pay any applicable supplementary charges. The interpretation and operation of the Warsaw Convention's liability limits may vary in each country. There are no specific stopping places which are agreed to and FedEx reserves the right to route the shipment in any way FedEx deems appropriate. ROAD TRANSPORT NOTICE. Shipments transported solely by road to or from a country which is a party to the Warsaw Convention or the Contract for the International Carriage of Goods by Road (the "CMR") are subject to the terms and conditions of the CMR, notwithstanding any other provision of this Air Waybill to the contrary. For those shipments transported solely by road, if a conflict arises between the provisions of the CMR and this Air Waybill, the terms of the CMR shall prevail. LIMITATION OF LIABILITY. If not governed by the Warsaw Convention, the CMR, or other international treaties, laws, or requirements, FedEx's maximum liability for damage, loss, delay, shortage, misdelivery, nondelivery, misinformation or failure to provide information in connection with your shipment is limited by this Agreement and as set out in the terms and conditions of the contract of carriage. Please refer to the contract of carriage set forth in the applicable FedEx Service Guide or its equivalent to determine the contractual limitation. FedEx does not provide cargo liability or off-risk insurance, but you may an additional charge for each additional U.S. \$100 (or equivalent local currency for the country of origin) of declared value for carriage. If a higher value for carriage is declared and the additional charge is paid, FedEx's maximum liability will be the lesser of the declared value for carriage or your actual damages. LIABILITIES NOT ASSUMED. IN ANY EVENT, FEDEX WON'T BE LIABLE FOR ANY DAMAGES, WHETHER DIRECT, INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL IN EXCESS OF THE DECLARED VALUE FOR CARRIAGE (INCLUDING BUT NOT LIMITED TO LOSS OF INCOME OR PROFITS) OR THE ACTUAL VALUE OF THE SHIPMENT, IF LOWER, WHETHER OR NOT FEDEX HAD ANY KNOWLEDGE THAT SUCH DAMAGES MIGHT BE INCURRED. FedEx won't be liable for your acts or omissions, including but not limited to incorrect declaration of cargo, improper or insufficient packaging, securing, marking or addressing of the shipment, or for the acts or omissions of the recipient or anyone else with an interest in the shipment or violations by any party of the terms of this agreement. FedEx won't be liable for damage, loss, delay, shortage, misdelivery, nondelivery, misinformation or failure to provide information in connection with shipments of cash, currency or other prohibited items or in instances beyond our control, such as acts of God, perils of the air, weather conditions, mechanical delays, acts of public enemies, war, strike, civil commotion, or acts or omissions of public authorities (including customs and health officials) with actual or apparent authority. NO WARRANTY. We make no warranties, express or implied. CLAIMS FOR LOSS, DAMAGE OR DELAY. ALL CLAIMS MUST BE MADE IN WRITING AND WITHIN STRICT TIME LIMITS. SEE OUR TARIFF, APPLICABLE FEDEX SERVICE GUIDE, OR STANDARD CONDITIONS OF CARRIAGE FOR DETAILS. The Warsaw Convention provides specific written claims procedures for damage, delay or non-delivery of your shipment. Moreover, the interpretation and operation of the Warsaw Convention's claims provisions may vary in each country. Refer to the Convention to determine the claims period for your shipment. The right to damages against us shall be extinguished unless an action is brought within two years, as set forth in the Convention. FedEx is not obligated to act on any claim until all transportation charges have been paid. The claim amount may not be deducted from the transportation charges. If the recipient accepts the shipment without noting any damage on the delivery record, FedEx will assume the shipment was delivered in good condition. In order for us to consider a claim for damage, the contents, original shipping carton and packing must be made available to us for inspection. MANDATORY LAW. Insofar as any provision contained or referred to in this Air Waybill may be contrary to any applicable international treaties, laws, government regulations, orders or requirements such provisions shall remain in effect as a part of our agreement to the extent that it is not overridden. The invalidity or unenforceability of any provisions shall not affect any other part of this Air Waybill. Unless otherwise indicated, FEDERAL EXPRESS CORPORATION, 2005 Corporate Avenue, Memphis, TN 38132, USA, is the first carrier of this shipment. Email address located at www.fedex.com.

Martin Nicole

From: Notifications@fedex.com
Sent: 1 juin 2005 12:10
To: Martin Nicole
Subject: FedEx Shipment 792294794046 Delivered

Our records indicate that the following shipment has been delivered:

| | |
|-------------------|------------------------------|
| Tracking number: | 792294794046 |
| Reference: | NICOLE MARTIN |
| Ship (P/U) date: | May 31, 2005 |
| Delivery date: | Jun 1, 2005 08:58 AM |
| Signed for by: | S.NICOLE |
| Service type: | FedEx International Priority |
| Packaging type: | FedEx Envelope |
| Number of pieces: | 1 |
| Weight: | 0.6 LB |

Shipper Information
MARIE PAPINUTTI
PROMETIC LIFE SCIENCES INC.
8168, CHEMIN MONTVIEW
MONT-ROYAL
PQ
CA
H4P2L7

Recipient Information
MATHEW DEAN
ARRIVA PHARMACEUTICALS INC.
2020 CHALLENGER DRIVE
ALAMEDA
CA
US
94501

Special handling/Services
Deliver Weekday

Please do not respond to this message. This email was sent from an unattended mailbox. This report was generated at approximately 11:01 AM CDT on 06/01/2005.

For questions about FedEx Express, please call us at 1.800.Go.FedEx.

All weights are estimated.

To track the status of this shipment online, please use the following:
[http://www.fedex.com/Tracking?tracknumbers=792294794046
&action=track&language=english&cntry_code=us&clienttype=ivpodalrt](http://www.fedex.com/Tracking?tracknumbers=792294794046&action=track&language=english&cntry_code=us&clienttype=ivpodalrt)

Thank you for your business.

Selon nos dossiers, l'envoi suivant a été livré:

| | |
|---------------------------|------------------------------|
| Numéro de suivi: | 792294794046 |
| Référence: | NICOLE MARTIN |
| Date d'expédition (ram.): | May 31, 2005 |
| Date de livraison: | Jun 1, 2005 08:58 AM |
| Signé par: | S.NICOLE |
| Type de service: | FedEx International Priority |
| Type d'emballage: | FedEx Envelope |
| Nombre de pièces: | 1 |
| Poids: | 0.6 LB |

Renseignements sur l'expéditeur
MARIE PAPINUTTI
PROMETIC LIFE SCIENCES INC.
8168, CHEMIN MONTVIEW
MONT-ROYAL

Renseignements sur le destinataire
MATHEW DEAN
ARRIVA PHARMACEUTICALS INC.
2020 CHALLENGER DRIVE
ALAMEDA

PQ
CA
H4P2L7

CA
US
94501

Services spéciaux/manutention spéciale
Deliver Weekday

Veuillez ne pas répondre à ce message. Ce courriel a été transmis à partir d'une boîte automatisée. Le rapport a été produit à environ 11:01 AM CDT le 06/01/2005.

Pour toute question sur FedEx Express, veuillez nous contacter au 1.800.Go.FedEx.

Tous les poids sont approximatifs.

Pour effectuer le suivi de cet envoi en ligne, cliquez sur le lien suivant:
[http://www.fedex.com/Tracking?tracknumbers=792294794046
&action=track&language=french&cntry_code=ca&clienttype=ivpodalrt](http://www.fedex.com/Tracking?tracknumbers=792294794046&action=track&language=french&cntry_code=ca&clienttype=ivpodalrt)

Nous vous remercions de votre confiance.